Recognizing the Invisible Symptoms of PsA to Close the Patient Communication Gap

Key Takeaways:

• While clinicians focus on joints, about 90 percent of patients struggle with debilitating fatigue, and 71 percent experience brain fog.
• Clinical "stability" in blood work does not equate to patient wellness, as only 1 percent of patients describe their quality of life as "excellent."
• Severe, chronic pain frequently persists without visible inflammation or swelling; failing to acknowledge this can lead patients to feel "medically gaslit."

For many patients living with psoriatic arthritis (PsA), the clinical reality documented in blood work and physical examinations often fails to capture the full scope of their daily burden. While clinicians prioritize slowing disease progression and managing visible inflammation, a significant communication gap persists regarding "invisible" symptoms.

These primarily include fatigue, sleep disturbances, chronic pain without overt swelling, and mental health struggles. Closing this gap is essential for improving patient satisfaction and long-term outcomes.¹

The burden of invisibility

A common theme among PsA patients is the discrepancy between their outward appearance and their internal state. In Health Union’s 2025 PsA In America survey, data reveal that while 89 percent of patients report painful or stiff joints, about 90 percent struggle with fatigue, and 71 percent experience brain fog.¹

Despite the prevalence of these symptoms, patients frequently feel their lived experience is dismissed if it is not reflected in laboratory results. As one respondent noted regarding their rheumatologist:¹

"He looks at my blood results and says, 'Well, your levels are stable'... he just focuses on my bloodwork results and tells me he will see me in 3 months... he is doing nothing to help me at all other than congratulating himself on a job supposedly well done."

This sentiment highlights a critical disconnect: For the patient, "stable" labs do not necessarily equate to a high quality of life. In fact, only about 1 percent of surveyed patients describe their current quality of life as "excellent," while 41 percent rate it as "fair" or "poor."¹

Often, inflammatory markers such as ESR and CRP can be normal, but the patient feels a subjective sense of inflammation and malaise in their body that is not detected by any objective blood test results or even imaging.

Fatigue impacts daily life

Clinicians must recognize that PsA-related fatigue is not synonymous with ordinary tiredness. Patients describe it as an "overwhelming complete mind and body takeover" that occurs regardless of sleep quality.¹

Data shows that 48 percent of patients are "unable" to participate in desired recreational activities, and 39 percent cannot walk 2 miles. This physical limitation often stems from a combination of chronic pain and "bone-deep" exhaustion.¹

Fatigue is often debilitating and affects a patient’s personal relationships and ability to function at work and participate in hobbies. It can even affect how a person sees themselves since they can no longer participate in the same activities and events that they once enjoyed.

The pain paradox

While clinical assessments often look for dactylitis or visible edema, many patients experience significant pain in their absence. Respondents expressed a desire for providers to understand that pain "ebbs and flows" and can be excruciating even when joints appear "normal" during an office visit.¹

Furthermore, the mental energy required to "mask" this pain leads to further depletion, with many patients reporting they "put on a brave face" even when suffering.¹

Impact on quality of life and mental health

The chronic nature of PsA takes a measurable toll on mental and emotional well-being. According to the In America survey data:¹

• 46 percent of patients worry "a lot" about their physical health.
• 31 percent report that PsA has a significant negative impact on their mental/emotional health.
• Only 18 percent strongly agree that their PsA is well-controlled with their current plan.

Patients often feel isolated, noting that even friends and family struggle to grasp the unpredictability of flares. One patient shared, "I wish my healthcare provider better understood how lost and insecure I am about this diagnosis and disease.”¹

Bridging the gap: Strategies for clinicians

To improve the patient-provider partnership, clinicians should consider the following:

• Validate the "invisible" – Explicitly screen for fatigue, brain fog, and emotional distress during visits, even if the patient appears "well."
• Move beyond the labs – Acknowledge that symptomatic relief is as vital to the patient as radiographic stability.
• Discuss treatment expectations – Only 12 percent of patients are currently in remission. Clear communication about the goals of therapy can help manage the frustration patients feel when they "do everything right" but still hurt.
• Holistic support – With 60 percent of patients open to clinical trials and 43 percent utilizing online support groups, providing resources for community and novel treatments can foster a sense of agency.
• Explore other reasons for pain and fatigue – Other pain conditions, such as fibromyalgia, can coincide with PsA, which can cause confusion since fibromyalgia can cause severe, widespread pain and fatigue, but lab values are normal.

Closing the communication gap

Closing the communication gap in PsA requires a shift from a purely clinical focus to one that incorporates the patient’s subjective experience. By recognizing and validating the profound impact of fatigue and "invisible" pain, clinicians can move toward a more empathetic, effective model of care that addresses the whole person, not just the pathology.